The trial, which started in Australia, aims at investigating ReActiv8 as a treatment for adults with debilitating chronic low back pain.
Enrollment of subjects is starting in the additional sites in Belgium.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
